Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
Sonowal exhorted young researchers and scientist to work on evidence based scientific research
This order is subject to initial advance payment as per the agreed terms of the contract
Receives regulatory approval for its molecule ‘Selumetinib’ in India
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Twelve hospitals across India will be part of the network which will support the trial in India
Subscribe To Our Newsletter & Stay Updated